Vanguard Group’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Vanguard Group’s Portfolio EPRS Stock Details EPRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-449,061	Closed	-$203K	–	4184
2016 Q2	$203K	Hold	449,061	–	–	﹤0.01%	3950
2016 Q1	$1.21M	Buy	449,061 +14,917	+3%	+$41.9K	﹤0.01%	3543
2015 Q4	$1.34M	Buy	434,144 +4,797	+1%	+$21.6K	﹤0.01%	3536
2015 Q3	$1.9M	Buy	429,347 +63,939	+17%	+$376K	﹤0.01%	3404
2015 Q2	$2.09M	Buy	365,408 +35,988	+11%	+$246K	﹤0.01%	3402
2015 Q1	$2.95M	Buy	329,420 +248,012	+305%	+$1.99M	﹤0.01%	3245
2014 Q4	$461K	Buy	81,408 +19,763	+32%	+$103K	﹤0.01%	3758
2014 Q3	$444K	Buy	+61,645	New	+$533K	﹤0.01%	3747

Other funds holding EPRS

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Vanguard Group's EPRS Position: Q3 2016 in Review

Vanguard Group sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q3 2016, closing a stake of 449,061 shares — an estimated $203K sold.

Vanguard Group first reported a position in EPRS in Q3 2014 and held it in 8 quarters. The position peaked at $2.95M in Q1 2015. 3 funds tracked by Wall St. Rank hold EPRS as of Q3 2016.

Vanguard Group reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q3 2016 after selling out during the quarter.
Vanguard Group sold 449,061 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q3 2016, an estimated $203K.
Vanguard Group first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q3 2014 and held it in 8 quarters.
Vanguard Group's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $2.95M in Q1 2015.
3 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q3 2016.

Based on Vanguard Group's 13F filing for Q3 2016, filed 14 Nov 2016.